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1. INTRODUCTION 
1.1. Porifera 
Sponges (phylum Porifera) represent a significant component of benthic communities 
worldwide. They populate mainly marine habitats, but are also found in freshwater (Taylor 
et al. 2007). Sponges are ancient metazoans, whose origins date back to the Precambrian 
more than 600 million years ago (Hentschel et al. 2002). So far, approximately 15,000 
species of sponges have been described, but their true diversity may be even higher. They 
populate the tropical oceans in great abundance and also inhabit temperate waters, from 
intertidal zones to the deep ocean (Thomas et al. 2010). Unpolluted littoral habitats harbor 
especially rich sponge faunas. Most littoral sponges are encrusting and form layers on 
hard surfaces, whereas benthic sponges, living on soft substrata, are upright and tall 
(Brusca & Brusca 1990). Only about 1% of the species live in freshwater (Belarbi et al. 
2003).  
Sponges are simple multicellular invertebrates that lack true tissues or organs. Main 
characteristics which define sponges are their unique aquiferous system and the highly 
totipotent nature of sponge cells (Brusca & Brusca 1990). The phylum Porifera consists of 
three classes, namely the Calcarea, Hexactinellida and Demospongiae. Sponge 
classification is mainly based on composition, size and shape of skeletal elements. The 
Calcarea have calciferous sclerites and occur predominantly in shallow waters. The 
skeleton of the Hexactinellida is characterized by siliceous spicules. Members of this class 
usually live in the deep sea. The Demospongiae, whose skeleton is composed of siliceous 
spicules and fibers of the protein spongin, constitute with approximately 85% the largest 
class in the phylum Porifera. Demospongiae are found from intertidal zones to the deepest 
seas (Hooper & Van Soest 2002).  
Sponges are sessile filter feeders, which pump large volumes of water through a 
specialized canal system and ingest organic particles such as algae and bacteria from the 
seawater. The expelled water is left essentially sterile (Fieseler et al. 2004). Sponges are 
hosts for a wide variety of microorganisms such as bacteria, fungi and microalgae, which 
can make up more than half of the biomass of the sponge host. The role of these 
associated microbes varies from source of nutrition to mutualistic symbiosis. Since 
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sponges are sessile organisms which lack physical protection, they have developed potent 
chemical defense mechanisms during evolution to protect themselves from predators, 
competitors and infectious microorganisms (Thomas et al. 2010). Sponges produce 
bioactive secondary metabolites, which are structurally highly diverse and of great interest 
for the development of new drugs. They are well known for their cytotoxic properties in 
general, further, they show specific antitumor, antiviral, and antimicrobial activities. Among 
marine invertebrates, sponges are the richest source for novel pharmacologically active 
compounds (Hentschel & Bringmann 2010; Thomas et al. 2010; Wang 2006). 
 
1.1.1. Anatomy and morphology 
Sponges are among the oldest of the multicellular animals and show little differentiation 
and coordination of tissues. However, sponge morphology is very diverse. There are 
encrusting, branching, cup-shaped and massive types with a wide range of colors. Their 
size varies from a few millimeters to more than a meter in diameter (Taylor et al. 2007).  
 
 
 
 
 
 
Figure 1: Diversity of marine sponges in size, shape and color. The common bath sponge 
Spongia officinalis (A), the giant barrel sponge Xestospongia muta (B), the branching 
sponge Axinella dissimilis (C and D). (Source: Encyclopedia of Life; www.eol.org) 
Environmental factors such as water current and depth exert a great influence on size and 
shape of the sponges, and coloration can be due to symbiotic bacteria or unicellular algae 
(Brusca & Brusca 1990). 
  
A 
D 
C B 
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Cells of sponges are mostly totipotent, retaining a high degree of mobility and capable of 
changing form and function. Although sponges are large-bodied multicellular animals, they 
share many functional characteristics with unicellular organisms, for instance in terms of 
nutrition, gas exchange and reproduction. The main feature of sponges, beside the highly 
totipotent nature of their cells, is the aquiferous system, an arrangement of water channels 
traversing the body (Brusca & Brusca 1990). Specialized flagellated cells, called 
choanocytes, are arranged as single-layered epithelium lining the internal surface. 
Choanocytes pump a unidirectional water current through the sponge’s body. The outer 
surface is constituted by epithelial cells called pinacocytes. Individual cells of this layer 
form pores (ostia), through which water passes from the exterior to the choanocyte-lined 
channels. Water is excreted through an apical opening called osculum. Between the 
internal flagellated epithelium (the choanoderm) and the external epithelium (the 
pinacoderm) lies the mesohyl, a greatly variable region which represents the connective 
tissue (Bergquist 1998).  
 
 
 
 
 
 
 
 
 
 
Figure 2:  Schematic diagram of a sponge. Arrows indicate the direction of water flow through 
the sponge. Image used with kind permission from Taylor et al. (2007).  
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The mesohyl consists of a collagenous matrix and contains mobile phagocytic and 
secretory cells, as well as, in most cases, mineral skeletal elements (spicules). Spicules 
are secreted by sclerocytes and are composed of either hydrated silica or calcium 
carbonate. Special cells, called spongocytes, secrete fibrous collagen referred to as 
spongin, which supports the mineral skeleton. In the well-known bath sponges, spongin 
fibers exclusively form elaborate strong skeletons (Bergquist 1998).  
The mesohyl ranges from thin to quite thick, and beside secretion of the skeleton it plays 
vital roles in digestion, gamete production, and transport of nutrients and waste products. 
With increasing mesohyl volume, the epithelial layers can increase their folding. A simple 
and continuous choanoderm, which is called asconoid condition, is found in some 
calcareous sponges. The syconoid condition is generated by simple folding of the 
pinacoderm and choanoderm. A greatly subdivided choanoderm into separate flagellated 
chambers produces the leuconoid condition. All members of the class Demospongiae, 
hence the majority of all sponges, show the complex leuconoid organization. In the 
mesohyl a great number of cell types may be found; most of them are able to change from 
one type to another as required. Large, highly motile cells called archaeocytes play a 
major role in digestion and food transport. These amoeboid cells - capable of phagocytosis 
- possess a variety of digestive enzymes (Brusca & Brusca 1990). 
 
 
 
 
 
 
Figure 3: Porifera body structures. Yellow: pinacocytes; red: choanocytes; 
grey: mesohyl; blue arrow: water flow. Source: Invertebrate 
Zoology (Ruppert et al. 2004). 
  
Asconoid Syconoid Leuconoid 
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1.1.1.1. Feeding 
Sponges are size-selective particle feeders and rely, unlike most metazoan, solely on 
intracellular digestion. They ingest particles such as organic molecules, bacteria and 
unicellular algae via phagocytosis and pinocytosis from the large volumes of water which 
is pumped through the body (Brusca & Brusca 1990). Some deep-sea sponges adapted to 
environments with a low particle concentration and still water conditions via developing a 
mechanism called carnivory. Carnivorous sponges show a fundamentally different body 
plan and are able to capture and digest swimming prey such as small crustaceans 
(Vacelet & Boury-Esnault 1995).  
1.1.1.2. Reproduction  
Sponges are capable of a variety of sexual and asexual reproduction strategies. With few 
exceptions, sponges are hermaphrodites. The majority is viviparous, releasing larvae; 
some species are oviparous and release zygotes into the water. Sponges do not feature 
gonads; sperms arise from choanocytes and occur in simple clusters, and eggs are formed 
from archaeocytes or choanocytes. Sperms are released from the osculum, and when they 
get into the aquiferous system of another sponge, they are phagocytosed by a 
choanocyte. The choanocyte then becomes amoeboid and transports the sperm to an egg. 
The carrier cell and the egg fuse with each other, and the sperm nucleus is transferred. 
Asexual processes of sponges include fragmentation, budding, and the formation of 
overwintering propagules called gemmules. Fragmentation primarily results from damage; 
a dislodged fragment may re-organize itself into a functional sponge. Budding is 
uncommon, but occurs in different manners in some species. The formation of gemmules 
happens in the mesohyl of a dying sponge from a cluster of nutrient-laden archaeocytes, 
which is encapsulated with a spongin shell. When environmental conditions permit, 
hatching takes place and a functional sponge is reconstituted from archaeocytes (Ruppert 
et al. 2004). 
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1.1.2. Associated microorganisms 
Sponges are well known to harbor a large community of microorganisms, which can 
constitute up to 60% of the sponge tissue volume (Usher et al. 2004), exceeding the 
number of bacteria in seawater by two to three orders of magnitude (Friedrich et al. 2001). 
The bacterial load in well-irrigated sponges is generally lower than in sponges with a poor 
irrigation system (Wilkinson 1978). Sponges with numerous associated bacteria (referred 
to as ‘high-microbial abundance sponges’ or ‘bacteriosponges’) are massive with a high 
tissue density, and usually larger than their low-microbial abundance counterparts. The 
microbe population consists mainly of extracellular bacteria which are embedded in the 
mesohyl matrix, but in some Demospongiae bacteria are also found intracellularly (Vacelet 
& Donadey 1977; Hentschel et al. 2006). The microbial distribution within a typical sponge 
follows a general pattern. The outer, light-exposed layers are populated by 
photosynthetically active microorganisms such as cyanobacteria, which provide the 
sponge with nutrients and cause coloration of the tissue. Heterotrophic and probably also 
autotrophic bacteria are located in the internal regions (Wang 2006). Sponge-associated 
bacterial phyla are for example Acidobacteria, Chloroflexi, Actinobacteria, Proteobacteria, 
Nitrospira, Bacteroidetes, and the sponge-specific Poribacteria (Fieseler et al. 2004). Also 
eukaryotic microbes such as dinoflagellates, diatoms, microalgae, and fungi occur in 
sponges (Taylor et al. 2007).  
The nature of sponge-microbe interactions varies from pathogenesis and parasitism 
(sometimes leading to sponge death) to microbes as the major food source (with the 
exception of phototrophic sponges), and to mutualistic or at least commensalistic 
associations. Sponges benefit greatly from the metabolic activities of their microbial 
partners. Cyanobacteria provide photosynthates and fixed nitrogen, and supply some 
phototrophic sponges commonly found on tropical reefs with more than 50% of their 
energy requirements. Sponges may also profit from nitrifying and sulfur-metabolizing 
microorganisms (Taylor et al. 2007). Further presumable benefits include stabilization of 
the sponge skeleton, processing of metabolic waste, and production of secondary 
metabolites (Hentschel et al. 2002).  
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Many sponge-derived bioactive compounds are suspected to be produced by symbiotic 
microorganisms (Thomas et al. 2010; Piel 2009; Wang 2006), since they show a high 
structural similarity to microbial natural products, e.g. complex polyketides or non-
ribosomal peptides from sponges and microorganisms exhibiting only slight differences in 
the substitution patterns (Piel 2004). A striking example is the cryptophycin family, which 
comprises a group of cytotoxic compounds initially isolated from bacteria. Cryptophycin-1 
was first isolated in 1990 from the cyanobacteria Nostoc spp. strain ATCC 53789, and re-
isolated in 1994 along with several analogues from another Nostoc spp. strain. The 
cytotoxic compound arenastatin A, isolated from the marine sponge Dysidea arenaria, was 
reported contemporaneously, and turned out to be identical to cryptophycin-24 (Molinski et 
al. 2009).  
 
 
 
 
 
 
Figure 4: Chemical structure of cryptophycins. 
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1.2. Drug development from marine natural products 
For thousands of years, natural products have been playing an important role for treatment 
of human diseases all over the world. Plants have formed the basis of traditional medicine 
systems; the first records, written on clay tablets, are from Mesopotamia and date from 
about 2600 years before Christ. Well-known medicinal plants like Papaver somniferum 
(opium poppy) or Glycyrrhiza glabra (licorice) and oils of Cedrus species (cedar) and 
Cupressus sempevirens (cypress) were already used back then (Newman et al. 2000). 
Natural product-derived drugs were mainly obtained from terrestrial plants prior to the 
discovery of penicillin by Fleming in 1928 and its development in the early 1940’s. The 
successful treatment of infections with β-lactams produced by fungi prompted intensive 
research in new antibiotics from microorganisms. Terrestrial bacteria and fungi are a 
plentiful source of structurally diverse bioactive substances. Today, therapeutic 
applications of metabolites from microorganisms and their derivates include treatment of 
infections (e.g. penicillins, cephalosporins, aminoglycosides, tetracyclins and many 
others), immunosuppression (e.g. cyclosporins and rapamycin) and anticancer therapy 
(e.g. pentostatin and epirubicin). Also cholesterol lowering agents like lovastatin and 
mevastatin, and the antidiabetic drug acarbose derive from microorganisms (Chin et al. 
2006).  
Marine organisms have a shorter history of utilization in the treatment of human disease. 
Approximately 60 years ago, the interest in marine natural products has increased. This 
was mainly due to refinements in technologies, e.g. scuba diving, which allowed the 
collection of source organisms. Investigations of marine natural products started with the 
pioneering work of Werner Bergmann (Molinski et al. 2009). In the early 1950s, Bergmann 
and co-workers reported on the bioactive nucleosides spongothymidine and 
spongouridine, which they had isolated from marine sponges (Bergmann & Feeney 1951; 
Bergmann & Burke 1955). These compounds led to the development of the anticancer 
agent cytarabine (Ara-C) and the antiviral compound vidarabine (Ara-A) and could be 
considered as the prototypes for all the modified nucleoside analogues that have been 
synthesized as antiviral and antitumor agents since that time (Newman et al. 2000). 
Cytarabine received approval by the US Food and Drug Administration (FDA) in 1969 and 
vidarabine in 1976. It has taken three decades for another marine-derived natural product 
to launch onto the market. The analgesic ziconotide (Prialt®), a synthetic equivalent of the 
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peptide ω-conotoxin MVIIA from the marine snail Conus magnus gained approval in 2004. 
Currently, it is labeled for the treatment of severe chronic pain in patients with cancer or 
AIDS. The anticancer agent trabectedin (Yondelis®), an alkaloid isolated from the tunicate 
Ecteinascidia turbinata, has been approved in the European Union in 2007 for patients 
with soft tissue sarcoma or relapsed platinum-sensitive ovarian cancer (Mayer et al. 2010). 
Finally, in November 2010, the anticancer agent eribulin mesylate has been approved by 
the FDA for the treatment of metastatic breast cancer. Eribulin mesylate is a synthetic 
analogue of halichondrin B, a polyether macrolide originally isolated from the marine 
sponge Halichondria okadai 25 years ago (Huyck et al. 2011). Approval from the European 
Medicines Agency (EMA) for eribulin was received in March 2011 (Eisai Co., Ltd. 2011). 
One of the major reasons why the field of drug development from marine natural products 
evolved slowly, was – and still is – the problem of sustainable supply with compounds 
isolated from source organisms for in vitro and in vivo studies. The amounts of bioactive 
substances, which can be recovered, are in general exceedingly small. Levels of 1 mg of 
compound per 3 kg of biomass are not uncommon (Newman & Cragg 2004). The isolation 
and purification of the active principles from the complex matrix of natural products 
remains, despite great advances in separation technology such as preparative high-
performance liquid chromatography (HPLC), often rate limiting. Due to the high structural 
complexity of the compounds with various chiral centers, synthesis is in many cases 
impractical. The problem of yielding sufficient quantities of pure material required for 
medicinal chemistry and development phases is particularly crucial for source organisms 
that have not been productively cultured, as is the case with marine sponges (Koehn & 
Carter 2005).  
Due to the difficulties associated with the development of drugs from natural sources, 
many pharmaceutical companies appreciated the era of combinatorial chemistry, 
neglecting the use of natural products in drug discovery in favor of high-throughput 
synthesis of large compound libraries (Paterson & Anderson 2005). An additional factor for 
decreased emphasis of research into natural products during the past two decades was 
the emergence of possible uncertainties with regard to collection of biomaterials as a 
consequence of the Convention on Biological Diversity (CBD) (Koehn & Carter 2005). The 
CBD was adopted in 1992; its principal objectives are conservation of biological resources, 
their sustainable use, and fair sharing of benefits arising out of their utilization. Article 15 of 
the CBD sets out, that access to genetic resources is subject to the prior informed consent 
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of the country where such resources are located, and to mutually agreed terms regarding 
the sharing of benefits (Garrity et al. 2009). 
Despite concerns about property rights and supply problems, almost half of the drugs 
approved since 1994 are based on natural products, and the interest in applying natural 
chemical diversity to drug discovery seems to be increasing again over the past years 
(Harvey 2008). This is partly based on the realization that modern technologies like 
combinatorial chemistry failed to provide new lead compounds in significant numbers, and 
partly due to new developments in analytical technology, spectroscopy and high-
throughput-screening, which made research in natural products more compatible to the 
requirements of the pharmaceutical companies once again (Molinski et al. 2009).  
The oceans, covering approximately 70% of the Earth’s surface, harbor an exceedingly 
high biodiversity whose exploration has only begun relatively recently, but already yielded 
more than 18,000 active compounds. Marine sponges are the richest source of novel 
natural agents from the sea, providing lead compounds against a wide range of human 
diseases. Due to large-scale screening programs of the US National Cancer Institute 
(NCI), research in antitumor agents has made the greatest progress, but also many 
compounds with properties such as anti-inflammatory, antiviral, antibacterial, and 
antifungal activity have been detected from sponges (Hentschel & Bringmann 2010). Other 
resources of marine natural products are microorganisms and phytoplankton, algae, 
cnidarians, bryozoans, mollusks, tunicates, echinoderms and intertidal plants (Blunt et al. 
2011).  
The following description of approved marine-derived drugs and some promising agents in 
development demonstrates on the one hand the great potential of marine organisms to 
provide new leads for drug development, on the other hand it points out the difficulties and 
in some cases extremely long duration of the progress from discovery to introduction on 
the market.  
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1.2.1. Approved marine-derived drugs 
1.2.1.1. Antimetabolites: Cytarabine and vidarabine  
Cytarabine (cytosine arabinoside, Ara-C), an anticancer agent currently available as either 
conventional cytarabine or liposomal formulation, was approved by the FDA in 1969. The 
synthetic pyrimidine nucleoside was developed from spongothymidine, an arabinose-
containing nucleoside originally isolated from the marine sponge Tethya crypta (Mayer et 
al. 2010). With the discovery of spongothymidine and spongouridine in the early 1950s by 
Bergmann and co-workers (Bergmann & Feeney 1951; Bergmann & Burke 1955), it was 
demonstrated for the first time that nucleosides using other sugars than ribose or 
deoxyribose naturally occur, and it was realized that biological activity of a nucleoside 
depends more on the base than on the sugar moiety. Hereupon, a vast number of 
derivates with modified sugar components were synthesized and tested as antiviral and 
antitumor agents. Compounds such as cytarabine, vidarabine, aciclovir, and 
azidothymidine can be traced back to these early discoveries (Newman et al. 2000).  
 
 
 
 
 
 
 
 
 
 
Figure 5: Naturally occurring nucleosides spongouridine and spongothymidine, and synthetic 
compounds cytarabine (cytostatic), vidarabine and aciclovir (virustatics).  
Spongouridine Spongothymidine 
Aciclovir Vidarabine Cytarabine 
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Cytotoxicity of cytarabine is based on inhibition of DNA polymerase and synthesis. After 
phosphorylation, the compound competes with the physiologic substrate deoxycytidine 
triphosphate. The antimetabolite is indicated for the treatment of different types of 
leukemia (Mayer et al. 2010). In acute myeloid leukemia, combination therapy of 
cytarabine with another agent, usually an anthracycline or anthracenedione, has been the 
mainstay of therapy for almost 40 years (Fernandez 2010). 
Vidarabine (adenine arabinoside, Ara-A) is a synthetic purine nucleoside with antiviral 
activity. The compound received the FDA approval in 1976 (Mayer et al. 2010). Adenine 
arabinoside is an inhibitor of viral DNA synthesis. Kinases encoded by viruses convert the 
agent into adenine arabinoside triphosphate, which inhibits viral DNA polymerase and 
hence DNA synthesis of herpes, vaccinia and varicella zoster viruses. Vidarabine has 
been used for the treatment of herpes virus infection. In the USA, its marketing has 
currently been stopped, as the newer drug aciclovir was found to be more efficient and 
less toxic. Though, vidarabine is probably capable of inhibiting aciclovir-resistant herpes 
and varicella zoster viruses (Sagar et al. 2010). 
 
1.2.1.2. Ziconotide 
Ziconotide (Prialt®), a marine-derived analgesic with a novel mechanism of action, which 
is applied for the treatment of severe chronic pain, received approval by the FDA in 
December 2004 and by the EMA in February 2005. Ziconotide is a synthetic form of ω-
conotoxin MVIIA, one of the numerous toxic peptides found in the venom of the fish-
hunting marine snail Conus magnus (Molinski et al. 2009). ω-Conotoxin MVIIA is a linear 
25 amino acid peptide comprising three disulphide bridges, which stabilize its well-defined 
three-dimensional structure (Price-Carter et al. 1998). The conopeptide was found to be 
neuroactive in 1979 via a bioassay which elicited a characteristic tremor in mice after 
intracerebral injection (Olivera et al. 1985). Complete synthesis of the peptide was 
achieved in 1987 (Olivera et al. 1987).  
Ziconotide acts as a reversible blocker of N-type voltage-sensitive calcium channels. 
These channels, occurring in the neural system, are expressed at high density on 
presynaptic terminals of primary afferent neurons that terminate in the dorsal horn of the 
spinal cord, an area which is important for processing pain. Activation of N-type channels 
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leads to calcium entry and subsequent release of pain-relevant neurotransmitters such as 
glutamate and neuropeptides. Binding of ziconotide to these channels inhibits calcium 
influx and thereby reduces neurotransmitter release at the first synapse in the nociceptive 
system, hence interrupting spinal transmission of pain information. As N-type calcium 
channels are widely distributed throughout the central nervous system, ziconotide-induced 
blockade can cause neurological side effects such as dizziness, confusion, ataxia, 
abnormal gait, memory impairment, nystagmus, or hallucinations (Schmidtko et al. 2010). 
Ziconotide has only a limited ability to cross the blood-brain barrier, and therefore requires 
intrathecal administration in order to achieve optimal analgesic efficacy with decreased 
potential for serious adverse effects. Ziconotide is non-addictive and does not lead to the 
development of tolerance (McGivern 2007). It is currently labeled for intrathecal 
management of severe chronic pain in patients with cancer or AIDS, who are intolerant of 
or refractory to other treatments such as systemic analgesics, adjunctive therapies, or 
intrathecal morphine (Mayer et al. 2010). 
 
 
 
 
 
 
 
 
 
Figure 6: Ziconotide, a linear 25 amino acid peptide with three disulfide bridges. 
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1.2.1.3. Trabectedin (ET-743) 
Trabectedin (Yondelis®), an alkaloid isolated from the tunicate Ecteinascidia turbinata, 
was approved for the treatment of refractory soft-tissue sarcomas by the EMA in July 2007 
(Molinski et al. 2009). Although antitumor activity of extracts from the ascidian has been 
reported since 1969, the structure of the active compounds was not identified for almost 
two decades. The most abundant active component, ecteinascidin-743, is an alkaloid 
composed of three tetrahydroisoquinoline units and is related to the microbially derived 
safracins and saframycins (Rinehart et al. 1990). As the yield for ecteinascidin-743 from 
Ecteinascidia turbinata is very low, significant amounts of the tunicate had to be collected 
to obtain sufficient material for in vitro and in vivo animal studies. Additionally, total 
synthesis of the compound was performed, but this was not practicable to provide enough 
material for further development. A breakthrough was achieved by the Spanish company 
PharmaMar, whose chemists performed a realizable semi-synthesis from the marine 
Pseudomonas fluorescens metabolite cyanosafracin B (Newman & Cragg 2004; Cuevas et 
al. 2000).  
 
 
 
 
 
 Figure 7: A practicable semi-synthesis of ecteinascidin-743 (right) from  
cyanosafracin B (left) was achieved by PharmaMar researchers. 
Trabectedin interacts with DNA repair mechanisms, primarily through the nucleotide 
excision repair (NER) system. The compound binds to the DNA minor groove and 
alkylates guanine at the N2 position, preferentially at guanine-cytosine rich sequences, 
and induces bending of DNA towards the major groove. Trabectedin arrests cells in 
G2 phase. This is in contrast to other alkylating agents, which are generally active in 
S phase. The main adverse effects are myelosuppression, transient transaminase 
elevation, nausea, emesis, and fatigue (Chuk et al. 2009).  
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In the European Union and several other countries, trabectedin is approved for the 
treatment of relapsed soft tissue sarcoma, and, in combination with pegylated liposomal 
doxorubicin, for the treatment of platinum-sensitive recurrent ovarian cancer. In the USA 
and in Switzerland, it holds orphan drug status for the treatment of advanced recurrent soft 
tissue sarcoma and ovarian cancer. Trabectedin is under development for prostate cancer, 
breast cancer and pediatric soft tissue sarcoma (Cassier et al. 2010). 
 
1.2.1.4. Eribulin mesylate (E7389) 
Eribulin mesylate (Halaven™; Eisai), approved by the FDA in November 2010 and by the 
EMA in March 2011 (Eisai Co., Ltd. 2011) for the treatment of metastatic breast cancer, is 
the product of nearly 25 years of struggle in the laboratory and stands for a hard-won 
victory for the total synthesis of natural products. Eribulin is a truncated synthetic analogue 
of halichondrin B, a cytotoxic compound discovered in 1986 from extracts of the marine 
sponge Halichondria okadai. Halichondrin B occurs in very low concentrations. The 
structure of the molecule is highly complex, comprising 32 stereocenters (Ledford 2010).  
Halichondrin B was shown to inhibit cell growth at nanomolar concentrations by a tubulin-
based mechanism of action (Bai et al. 1991). In 1992, total synthesis of halichondrin B via 
complex reactions comprising approximately 90 steps was reported (Aicher et al. 1992). 
The discovery of the deep-water sponge Lissodendoryx n. sp. 1, which also sequesters 
halichondrins, led to the harvest of approximately 1 tonne of this sponge by trawling from 
natural habitats. Isolation of the cytotoxic compounds resulted in a yield of 310 mg 
halichondrin B and a comparable amount of isohomohalichondrin B, which was sufficient 
material for initial preclinical trials only. Aquaculture feasibility trials were carried out to 
establish an option for the supply with halichondrins. The survival and growth of the 
sponge culture was highly dependent on season, water temperature and depth, further, 
the production of halichondrin B was lower than in wild-type samples of Lissodendoryx 
(Munro et al. 1999). A breakthrough was achieved by the synthesis of simplified 
analogues, which showed equipotent anticancer activity compared to the natural product 
(Molinski et al. 2009). Besides retaining the biological activity of the parent compound, the 
development candidate eribulin mesylate (E7389) also showed favorable pharmaceutical 
characteristics including water solubility and chemical stability (Mayer et al. 2010).  
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Figure 8:  Halichondrin B, a cytotoxic compound isolated from marine sponges, 
and the truncated synthetic analogue eribulin mesylate (E7389). 
 
Eribulin is, like the widely used taxans and the vinca alkaloids, a tubulin-targeted agent, 
but inhibits the microtubule dynamics through a distinct mechanism (Jordan et al. 2005). It 
inhibits the growth of microtubules and sequesters tubulin into non-productive aggregates, 
which leads to G2/M cell cycle arrest, disruption of mitotic spindles and apoptotic cell 
death after prolonged mitotic blockade (Huyck et al. 2011). Dose-limiting toxicities of 
eribulin mesylate include leukopenia, fatigue and neuropathy. In Phase II studies, the 
response rate against breast cancer in heavily pre-treated patients was approximately 
10% (Cortes et al. 2010; Vahdat et al. 2009). Eribulin possesses the potential to overcome 
acquired drug resistance in metastatic breast cancer; a Phase III trial showed an average 
improvement of 2.5 months in overall survival. Several Phase II trials are ongoing for 
further evaluation of the efficacy of eribulin in other cancer types including soft tissue 
sarcoma, colon cancer, prostate cancer and non-small-cell lung cancer (Huyck et al. 
2011). 
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1.2.2. Agents in development 
1.2.2.1. Plitidepsin 
Plitidepsin (Aplidin®) is a cytotoxic depsipeptide originally isolated from the tunicate 
Aplidium albicans. The compound is currently in Phase II clinical trials for the treatment of 
solid and hematologic malignancies. It has been granted the orphan drug designation for 
the treatment of acute lymphoblastic leukemia and multiple myeloma by the EMA and the 
FDA (Rockwell & Y. Liu 2010). Plitidepsin induces apoptosis through a mechanism which 
is not fully elucidated yet; oxidative stress and activation of the Rac1-JNK pathway seem 
to play a major role. Additionally, the compound exhibits antiangiogenic activity through 
inhibiting the expression of vascular endothelial growth factor (VEGF) and its receptor 
(Dumez et al. 2009). Plitidepsin is currently obtained by multistep total synthesis from 
constituent amino acids, due to the fact that supply from nature is limited by the rare 
occurrence of the source organism and the lack of feasible aquaculture conditions 
(Molinski et al. 2009). 
 
 
 
 
 
 
 
Figure 9: Plitidepsin (Aplidin®), a depsipeptide isolated from the tunicate Aplidium albicans. 
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1.2.2.2. (+)-Discodermolide 
(+)-Discodermolide is another example for a highly potent and promising antitumor 
compound, which can be isolated from the source organism only in minute amounts. It 
features a highly complex structure, thus representing a daunting target for large-scale 
chemical synthesis. The polyketide, possessing cytotoxic and immunosuppressive 
properties, was isolated from the Caribbean sponge Discodermia dissoluta and first 
reported in 1990. Its mechanism of action – microtubule stabilization – is similar to 
paclitaxel, but (+)-discodermolide is ten times more potent. Additionally, it is strongly 
effective against P-glycoprotein (P-gp)-expressing multiple drug resistant (MDR) tumor 
cells (Koehn & Carter 2005). The compound was shown to inhibit in vitro cancer cell lines, 
which are resistant to paclitaxel (Valderrama et al. 2010). Several research groups 
developed methods for the synthesis of (+)-discodermolide, e.g. Smith et al. (2000), 
Paterson et al. (2000) and Harried et al. (2003). After the development of an efficient large-
scale synthetic route by a working group of the pharmaceutical company Novartis (Mickel 
et al. 2004), (+)-discodermolide entered into clinical trials, but further studies were halted 
due to toxicity problems. As the work on the synthesis of various analogues is continuing, 
it is very likely that a derivate of (+)-discodermolide may become a clinical candidate in the 
future (Kingston 2009).  
 
 
 
 
 
 
Figure 10: Discodermolide, isolated from the marine sponge Discodermia dissoluta. (Photo 
courtesy of Florida Atlantic University, Harbor Branch Oceanographic Institute.) 
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1.2.2.3. Hemiasterlin 
Hemiasterlin, first reported in 1994, is an antimitotic tripeptide which was isolated from the 
sponge Hemiasterella minor (Talpir et al. 1994). The related isomers hemiasterlin A and B, 
which were found in other sponges, were described one year later (Coleman et al. 1995) 
and a fourth analogue was reported in 1999 (Gamble et al. 1999). All hemiasterlins 
showed high cytotoxicity against a variety of cultured cell lines, acting through induction of 
mitotic arrest in the metaphase. A simpler and more potent synthetic analogue of 
hemiasterlin, HTI-286, completed an open-label Phase I clinical trial in patients with 
advanced solid tumors. As no objective responses were observed, Phase II trials have 
been halted (Molinski et al. 2009). Currently, the novel synthetic analogue E7974 is 
undergoing phase I clinical trials for cancer. This compound was synthesized in the course 
of a lead optimization program of the Eisai Research Institute (Andover, Massachusetts, 
USA). E7974 acts via a tubulin-based antimitotic mechanism, predominantly targeting 
α-tubulin. This is in contrast to other tubulin-targeted agents, such as the taxanes and 
vinca alkaloids, which bind to β-tubulin. E7974 shows high in vivo antitumor efficacy even 
in tumor models which are resistant to paclitaxel; it retains strong potency in cells 
harboring mutations of β-tubulin, as it is the case with cells resistant to the taxanes. 
Further, it shows low susceptibility to P-gp-mediated efflux. Based on these promising 
findings, E7974 was selected for clinical evaluation for the treatment of solid tumors 
(Kuznetsov et al. 2009). 
 
 
 
 
 
Figure 11:  Chemical structures of the naturally occurring compound hemiasterlin (isolated from 
the sponge Hemiasterella minor), and the synthetic analogues E7974 and HTI-286. 
  
Hemiasterlin 
HTI-286 E7974 
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1.2.2.4. Dolastatin analogues 
The dolastatins, whose discovery had its beginnings in 1972, are a class of related 
cytotoxic peptides isolated from the sea hare Dolabella auricularia. Among these 
compounds, dolastatin 10 exhibited exceptionally potent in vitro cytotoxic activity against 
various cancer cell lines (Pettit et al. 1987). The antimitotic agent acts via inhibition of 
tubulin polymerization in a similar way to the vinca alkaloids (Bai et al. 1990). Dolastatin 10 
entered Phase I clinical trials in the 1990’s and progressed to Phase II trials under the 
auspices of the NCI for the treatment of several solid tumors. As no significant antitumor 
activity could be detected, the compound was withdrawn from clinical trials (Kingston 
2009; Molinski et al. 2009). Until recently, soblidotin, a simplified analogue of dolastatin 10, 
and tasidotin, a synthetic dolastatin 15 derivate, were in clinical trials, but have been 
discontinued as well (Mayer et al. 2010; Midwestern University 2011). 
 
 
 
 
Figure 12: The antimitotic peptide dolastatin 10, isolated in the 1970’s from the sea hare 
Dolabella auricularia, was the first member of the dolastatin family which entered 
clinical trials.  
 
1.2.2.5. Cyclodepsipeptides with antiviral and antitumor activity 
A number of cyclic depsipeptides, isolated from various marine sponges, e.g. papuamides 
and mirabamides, have been shown to exhibit antiviral activity in vitro via inhibition of HIV 
entry into cells. Other cyclodepsipeptides, e.g. jasplakinolide, arenastatin A and 
spongidepsin, possess potent in vitro cytotoxic activity and may be of interest in the 
development of new anticancer agents. The compounds kahalalide F, a depsipeptide 
isolated from mollusks and from the green alga Bryopsis sp., and plitidepsin (Aplidin®, see 
chapter 1.2.2.1) have already shown promising results in phase I and II clinical trials 
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(Andavan & Lemmens-Gruber 2010). The cryptophycins, isolated from the cyanobacteria 
Nostoc spp. and from the sponge Dysidea arenaria (see also chapter 1.1.2), are highly 
potent cytotoxic agents (Beck et al. 2005). The synthetic analogue cryptophycin-52 (see 
Figure 4) entered clinical trials, but failed to produce an objective response in a phase II 
study for advanced non-small-cell lung cancer (Edelman et al. 2003). Several new 
cryptophycin analogues have been synthesized and undergone preclinical efficacy studies 
over the past years, some of them being considered as second-generation clinical 
candidates (Liang et al. 2005; Liu et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Chemical structures of cyclodepsipeptides produced by marine organisms. 
   
Papuamide A R1 = CH3 
Papuamide B R1 = H 
Kahalalide F Jasplakinolide  
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2. OBJECTIVE 
In drug discovery from natural sources, bioassay guided fractionation is an appealing 
strategy for the isolation of active compounds (Houssen & Jaspars 2006; Koehn & Carter 
2005). In the present study, this method was applied for the isolation of the cytotoxic 
component of a marine sponge extract. The assay used to determine toxicity was the brine 
shrimp lethality assay (BSLA). This test is based on the ability of extracts, fractions, or 
pure compounds to kill Artemia salina (brine shrimp) nauplii. 
The first task of this work was the selection of a sponge sample with considerable toxicity 
for bioassay guided fractionation. 40 extracts of Caribbean marine sponges, yielded via 
ultrasonic-assisted solvent extraction with CH2Cl2/MeOH (1:1), were provided from INBio 
(access permit granted by CONAGEBIO♣), and were tested for their cytotoxicity against 
Artemia salina. The sample with the lowest median lethal concentration (LC50) value in the 
BSLA, also showing high toxicity against human and murine cancer cells, was selected for 
fractionation. 
The aim of this study was the isolation of the toxic component from the selected sponge 
sample. The extract was initially fractionated via vacuum liquid chromatography (VLC). As 
a first approach, to get an overview about the composition of the fraction with the highest 
toxicity, both analytical high performance liquid chromatography (HPLC) and semi-
preparative HPLC were applied. For further fractionation, the preparative HPLC instrument 
BioXplore© (Varian) was used to separate the purified ethanol extract. 
The individual fractions obtained by the VLC and HPLC separations were tested in the 
BSLA and LC50 values were calculated. Additionally, thin layer chromatography (TLC) was 
used to monitor the process and identify the toxic compound. 
  
                                                
♣ Costa Rica is a country with an exceptionally great diversity of species and ecosystems. For the 
conservation and sustainable use of its biodiversity, a very comprehensive legal framework has 
been established, which includes the Biodiversity Law, approved in 1998. This law states, that any 
research program or bioprospecting requires an access permit, which has to be granted by the 
National Commission of Biodiversity Management (CONAGEBIO) (INBio 2011; Solís & Madrigal 
1999). 
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3. EXPERIMENTAL 
3.1. Sponge samples 
Starting materials were extracts of 40 Caribbean marine sponges (the extracts collection 
was used thanks to CONAGEBIO’s ex-situ access permit R-CM-INBio-121-2010-OT), 
which were adsorbed on a styrene-divinylbenzene resin (Diaion™ HP-20). The marine 
sponges were collected in 2002 and 2003 in the Caribbean Sea of Costa Rica by scuba 
diving at a depth of 8 – 30 meters.  
The further investigated sponge sample (INBio code 290-13443, laboratory code 999; 
election based on cytotoxicity assay, see below) was collected at 8 m depth (flat bottom) at 
Cahuita Point, Costa Rica, on September 10, 2002. The sponge was hard and easy to 
tear, had an encrusting, tree like shape and a lumpy surface, the color was off-white inside 
and purple on the upper surface. A voucher specimen was deposited at INBio, Santo 
Domingo de Heredia, Costa Rica. The sponge belongs to the order Haplosclerida (class 
Demospongiae), probably to the genus Haliclona (classified by Dr. Sven Zea, National 
University of Colombia, Department of Biology and Center of Marine Sciences CECIMAR). 
 
 
 
 
 
 
 
 
Figure 14: Voucher specimen (A and B) and characteristic spicules (C and D) of the further 
investigated marine sponge. 
A B C 
D 
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3.2. Materials 
Solvents for purification and fractionation: 
Dichloromethane 
CAS 75-09-2 
 
Reactivos quimicos Gamma® 
Laboratorios quimicos ARVI S.A. 
(CH2Cl2, 99.5%) 
 
Ethanol 95 % 
CAS 64-17-5 
Fábrica Nacional de Licores 
Grecia, Alajuela 
 
Isopropanol 
CAS 67-63-0 
 
Reactivos quimicos Gamma® 
Laboratorios quimicos ARVI S.A. 
(C3H8O, 99.5%) 
 
Methanol 
CAS 67-56-1 
 
Methanol for liquid chromatography LiChrosolv® 
Merck Chemicals  
(CH3OH, 99.8%) 
 
Distilled water  
 
Adsorbent resin: 
Supelco Diaion™ HP-20  
(Particle size 250-850 μm) 
Supelco Diaion™ HP-20SS 
(Particle size 75-150 μm) 
Sigma-Aldrich®, Bellefonte, PA 
Matrix: styrene-divinylbenzene  
Surface area: ~500 m2/g 
 
Thin layer chromatography (TLC): 
Stationary phase: 
Silica on TLC Alu foils 
 
Silica gel matrix, 20 cm x 20 cm,  
with fluorescent indicator 254 nm 
Fluka® Analytical, Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
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Solvents for mobile phases: 
Dichloromethane 
CAS 75-09-2 
 
Reactivos quimicos Gamma® 
Laboratorios quimicos ARVI S.A. 
(CH2Cl2, 99.5%) 
 
Methanol 
CAS 67-56-1 
 
Methanol for liquid chromatography LiChrosolv® 
Merck Chemicals  
(CH3OH, 99.8%) 
 
Toluene 
CAS 108-88-3 
Fisher Scientific Company 
Fair Lawn, NJ 
(C6H5CH3, 99%) 
 
p-Dioxane 
CAS 123-91-1 
Spectrum Chemical Mfg. Corp. 
Gardena, CA; New Brunswick, NJ 
(C4H8O2, 99.0%) 
 
1-Butanol 
CAS 71-36-3 
 
Reactivos quimicos Gamma® 
Laboratorios quimicos ARVI Ltda. 
(C4H10O, 99.4%) 
 
Glacial acetic acid 
CAS 64-19-7 
 
Reactivos quimicos Gamma® 
Laboratorios quimicos ARVI Ltda. 
Grado reactivo A.C.S. 
 
Distilled water 
 
 
 
Spray reagents: 
Vanillin-sulfuric acid (Jork et al. 1994) 
Potassium permanganate (Krebs et al. 1969) 
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Cytotoxicity assay: 
Artemia salina cysts Acuario Flora y Fauna  
Guadalupe, Costa Rica 
 
Sea salt Instant Ocean® – Synthetic Sea Salt 
Aquarium Systems 
Sarrebourg, France; Mentor, Ohio  
 
Dry yeast Levadura en grano Yerona 
DIPROA S.A.  
Moravia, San José, CR 
 
Antichlor (sodium thiosulfate) 
 
Nutrafin® Aqua plus  
Hagen/Canada 
 
Dimethyl sulfoxide (DMSO)  
Reagent A.C.S. 
CAS 67-68-5 
 
Spectrum Chemical Mfg. Corp.  
Gardena, CA; New Brunswick, NJ  
((CH3)2SO, 99.9%) 
 
Thermostat PENN-PLAX®  
Therma-Flow “PC” Plus Heater 
Automatic moisture-proof aquarium heater 
 
Aquarium air pumps 
 
PENN-PLAX®  
AirTech 2K1TM  
AirTech 2K2 TM  
 
pH meter pH/mV/Temp. Meter SUNTEX 
Model SP-701 
 
Light source 
 
Sylvania Cool White 20 W 
Model F20T12/CW  
 
Stereo microscope 
 
Carl Zeiss  
Stemi 2000-C 
 
Eppendorf adjustable pipettes 10-100 µl 
100-1000 µl 
Multichannel (12-channel), 30-300 µl 
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3.3. Methods  
3.3.1. Sponge extraction  
The sponges were extracted by ultrasonic-assisted solvent extraction with CH2Cl2/MeOH 
(1:1).  
Immediately after collection of the marine sponges, they were preserved in a solution of 
50% seawater and 50% EtOH for transport. Further sample preparation included 
discarding the stabilizing solution, homogenization of the sponges, and extraction of the 
sponge material with CH2Cl2/MeOH (1:1) in the ultrasonic bath for 30 minutes. Afterwards 
the mixture was transferred into a percolator; CH2Cl2/MeOH (1:1) was added and after 8 h 
the solvent was filtered off. The sponge material was extracted two more times in the 
percolator (12 h and 4 h, respectively), and the filtrates were combined. Solvent was 
removed using a rotary evaporator. Finally the extract was allowed to absorb onto the 
resin HP-20 which was then evaporated to dryness in a fume hood, and the samples were 
stored at -20°C.  
 
3.3.2. Chromatography 
3.3.2.1. Vacuum liquid chromatography (VLC) 
VLC is a form of column chromatography which uses reduced pressure to increase the 
flow rate of the mobile phase. Operating VLC, the column is eluted with the appropriate 
solvents and allowed to run dry after each fraction is collected.  
In the present work, the basic mechanism of VLC was adopted for small-scale purification 
of crude sponge extracts to obtain ethanol fractions for testing the cytotoxicity by means of 
the brine shrimp lethality assay (BSLA). Furthermore, the technique was used for the 
fractionation of two ethanol extracts that were active in the bioassay. The mode of 
separation was reversed-phase chromatography, a styrene-divenylbenzene polymer 
serving as stationary phase. 
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Small-scale purification of 40 sponge samples: 
With a portion of each sponge extract, a pre-purification step was carried out in order to 
obtain purified material, in which secondary metabolites were concentrated and separated 
from sugars, salts, fats and other concomitant substances. For each sample approximately 
2 ml of the resin Diaion™ HP-20, charged with crude sponge extract, were used.  
Purification was carried out with a Supelco Visiprep™ Solid Phase Extraction (SPE) 
Vacuum Manifold, 12-Port Model and 6 ml glass reaction tubes with Teflon® frits and a 
bed of approximately 2 cm HP-20 resin. The extract was eluted with 15 ml distilled water 
(fraction 1), EtOH (fraction 2) and CH2Cl2/EtOH (1:1) (fraction 3). The obtained fractions 
were collected in 20 ml glass vials and evaporated using a Speed Vac Concentrator 
Savant SC 210A, stored in a freezer at -20°C over night and then lyophilized via a FTS 
Systems™ Lyophilisator. The ethanol fractions were later subjected to cytotoxicity testing 
via the BSLA (see chapter 3.3.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Supelco Visiprep™ SPE Vacuum Manifold, used for  
small-scale purification of the crude sponge extracts. 
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Fractionation of two active samples: 
The large-scale purified samples 998 and 999 (see following chapter) were fractionated via 
VLC, and the fractions were tested for their toxicity. First, the purified ethanol fractions 
were absorbed on the resin HP-20 by re-dissolving the extracts in a small amount of EtOH, 
adding resin HP-20 (five times the quantity of extract), and gently removing the solvent by 
a rotary evaporator.  
Further, ethanol slurry of HP-20SS (resin which consisted of a smaller grain size) was 
filled into a chromatography column (30 cm l x 1 cm id). The resin was vacuum dried, and 
the column was washed with water and equilibrated with EtOH/water (2:8). Following, 
approximately 5 ml of the dried, extract-charged resin was poured onto the 12 cm bed. 
The column was eluted with 15 ml EtOH/water (2:8) (fraction 1), EtOH/water (1:1) 
(fraction 2), EtOH/water (8:2) (fraction 3), EtOH (fraction 4), and isopropanol/CH2Cl2 (8:2) 
(fraction 5) by applying vacuum. The fractions were collected in 20 ml glass vials, dried 
using a Speed Vac Concentrator, and subjected to the BSLA. 
 
3.3.2.2. Purification via pressurized column chromatography 
Based on the results of the cytotoxicity assay (see chapter 4.1.3), the samples 998 and 
999 were chosen for further separation; therefore, a larger quantity of purified extract was 
required. The purification was carried out by means of the “charging station”, which is a 
particular equipment capable of cleaning up large amounts of crude extracts within a short 
time. The instrument holds two columns with a capacity of 250 ml each, and works with a 
maximal pressure of 2000 psi (~13.8 MPa). Solvents are conducted from the tank to the 
previously filled column and pressed through it.  
Approximately 80 ml of the HP-20 resin charged with crude extract (4-5 g) were filled into 
the high-pressure column, further fresh HP-20 resin was poured in and it was locked. Then 
the device was placed in-line and the extract was eluted with 500 ml of distilled water 
(fraction 1), 1000 ml EtOH (fraction 2) and 1000 ml CH2Cl2/EtOH (1:1) (fraction 3). The 
collected fractions were evaporated to dryness using a rotary evaporator and weighed.   
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Figure 16: The charging station (A), equipped with a high-pressure column (B), was used for 
purification of crude extracts.  
 
3.3.2.3. Thin layer chromatography (TLC) 
TLC was employed for monitoring the composition of the fractions obtained by VLC and 
HPLC. TLC was carried out on silica gel TLC plates with fluorescent indicator 254 nm. The 
chromatograms were prepared by applying sample solutions with a concentration of 
10 mg/ml and developed under saturated conditions. Running distance was 8 cm. 
Mobile phase: 
• dichloromethane – methanol (95:5) 
• toluene – p-dioxan – glacial acetic acid (45:12:2) 
• 1-butanol – glacial acetic acid – water (4:1:1) 
The spots were first detected under UV-light (254 and 365 nm). For better visualization, 
the TLC plates were sprayed with the detection reagents vanillin-sulfuric acid and 
A 
B 
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potassium permanganate respectively, and heated until coloration appeared. 
Characterization was performed by calculation of the retention factor (Rf) according to the 
following equation:  
Rf = 
Distance traveled by compound
Distance traveled by solvent
 
 
3.3.2.4. High Performance Liquid Chromatography (HPLC) 
HPLC was used for further separation of the fractions obtained by VLC, which were active 
in the BSLA. Several water/MeOH gradients were tested using an XTerra® RP-18 column 
(3.9 x 150 mm). The best conditions were obtained by the gradient shown in Table 1. 
Further, this gradient was applied for semi-preparative HPLC separation employing a 
10 x 250 mm column. Degassing of solvents was achieved by placing the container into an 
ultrasonic bath before use. Samples were diluted in MeOH at a concentration of 25 mg/ml.  
Instrument: Waters  600E Multisolvent delivery system  
  (pump and controller) 
  2487 Dual λ Absorbance Detector 
 Rheodyne  7725i Manual Injector 
  7161 injection valve  
 Software:  Millennium³² 
 
Columns: XTerra® (Waters, Ireland) 
 RP-18    5 µm RP-18    10 µm 
 3.9 x 150 mm 10 x 250 mm 
 Part.No. 186000480 Part.No. 186001028 
 SN 01913729713638  SN 11813634012601 
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Fractionation conditions:  
 
Mobile phase A:  Distilled water 
Mobile phase B:  MeOH  
Flow:  1 ml/min (column 3.9 x 150 mm) 
  3 ml/min (column 10 x 250 mm) 
Injection volume: 20 µl (column 3.9 x 150 mm) 
  100 µl (column 10 x 250 mm) 
UV Detection:  254 and 280 nm 
 
Table 1: Gradient system developed for semi-preparative HPLC separation. 
Time 
(min) 
Mobile phase A 
(v/v) 
Mobile phase B 
(v/v) 
00 → 30 65 → 00 35 → 100 
30 → 35 00 → 00 100 → 100 
35 → 40 00 → 65 100 → 35 
40 → 45 65 → 65 35 → 35 
 
 
3.3.2.5. BioXplore© fractionation technology 
The BioXplore© equipment is an industrial HPLC system which can be applied for the 
fractionation of different types of samples, e.g. plant material, marine organisms and 
culture broths. The unit is equipped with two detectors, an evaporative light scattering 
detector (ELSD) and a variable wavelength detector. In the present work, the BioXplore© 
technology was employed for fractionating the purified ethanol extract of sample 999. 
Approximately 50 mg of extract were dissolved in 20 ml ethanol. The compounds were 
eluted applying a step gradient of ethanol and distilled water (see Table 2 and Figure 18), 
and ELSD peak-based collection was carried out manually. The obtained fractions were 
evaporated to dryness and tested in the BSLA. 
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Instrument:   BioXplore 300, Model ST 400, custom made HPLC by Varian  
   Sedex 55 Evaporative Light Scattering Detector 
   Knauer Variable Wavelength Detector 
   Varian ProStar HPLC Fraction Collector  
   Rheodyne 3725-038 Injector 
   Demicap filter capsules, Peplyn Plus Membrane 
   LC ReSponder™ Control Software 
Column:   Grace Vydac Flanged MODcol® 
   50.8 x 250 mm 
   Packing material: Kromasil C18, 10 µm 
   Volume of stationary phase: 500 ml 
 
 
 
 
 
 
 
 
 
Figure 17: Industrial HPLC unit BioXplore 300, custom made by Varian.  
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Fractionation conditions: 
Mobile phase A:  Distilled water 
Mobile phase B:  Ethanol 95% 
Flow:  80 ml/min 
Injection volume:  20 ml 
Detection: ELSD 
 
Table 2: Gradient system applied for BioXplore© separation. 
Time 
(min) 
Mobile phase A 
(v/v) 
Mobile phase B 
(v/v) 
0 → 5 90 10 
5 → 12 65 35 
12 → 19 40 60 
19 → 26 15 85 
26 → 51 0 100 
 
 
              
% Ethanol               
                
100         25 min     
                
85       7 min       
                
60     7 min         
                
35   7 min           
                
10 5 min             
                
  0 5 12 19  26 51 min 
                
Figure 18: Step gradient applied for fractionation via BioXplore© technology. 
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3.3.3. Cytotoxicity test: Brine shrimp lethality assay (BSLA) 
The BSLA was used for the toxicity assessment of purified sponge extracts and fractions 
thereof. The test is based on the ability of extracts and compounds to kill laboratory-
cultured Artemia salina larvae.  
Artemia salina is a small crustacean of the Artemiidae family, reaching a size of 
approximately 15 mm (Schminke 2007). Dried cysts of the brine shrimp are commercially 
available, remain viable for years and can be hatched easily (Vanhaecke et al. 1981).  
Artemia salina cysts were purchased from the aquaristic shop Acuario Flora y Fauna, 
Guadalupe, Costa Rica. 
 
 
 
 
 
 
 
Figure 19: Magnified view of Artemia salina.  
(Source: www.flickriver.com/photos/xavipat/4451152486) 
 
3.3.3.1. Test conditions  
In the present work, the test was carried out as a microplate assay in 96-well microtiter 
plates, developed by Solis et al. (1993). A preliminary screening was performed to detect 
samples with significant activity. For this purpose, four different concentrations (500, 250, 
125 and 62.5 µg/ml) of purified sponge extracts were tested in duplicate. For the definitive 
test, eight different concentrations (1000, 500, 250, 125, 62.5, 31.3, 15.6 and 7.8 µg/ml) 
were used and three replicates were accomplished. Control wells with 5% dimethyl 
sulfoxide (DMSO) in artificial seawater, used as solubilizer, were included in each 
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experiment. Extracts of Persea americana (avocado) seeds, whose activity in the BSLA 
has been confirmed (Leite et al. 2009), served as positive control. 
 
3.3.3.2. Hatching of nauplii 
Artificial seawater was prepared in a 2 liter glass beaker by dissolving 28 g of synthetic 
sea salt (Instant Ocean®) in 1 liter of commercially available purified drinking water. 3 mg 
of dry yeast and 1 drop of antichlor (sodium thiosulfate) solution were added. The pH value 
was adjusted to 8.5 with 1N NaOH. Approximately 100 ml of the artificial seawater were 
taken and stored in the refrigerator (+6°C) for further preparation of the samples and 
microplates (see chapter 3.3.3.3 and 3.3.3.4). The beaker with the remaining solution was 
put into a water tank at 28-30°C, and the artificial seawater was strongly aerated via two 
aquarium air pumps. Approximately 1 g of dried Artemia salina cysts were added and 
incubated for 24 hours under continuous aeration and illumination.  
 
 
 
 
 
 
 
 
Figure 20: Hatching of Artemia salina nauplii at 28-30°C under aeration and illumination for 24 h.  
The hatched nauplii are phototropic and accumulate at the lightened side. By stopping 
aeration, they could easily be collected with a graduated pipette and were transferred into 
a petri dish. 
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3.3.3.3. Sample preparation 
Stock solutions of 2000 µg/ml (and 1000 µg/ml for the pre-selection step, respectively) of 
the sponge extracts were prepared in artificial seawater. For this purpose, 1-3 mg of the 
ethanol fractions obtained in the purification step were precisely weighed into 1.5 ml 
Eppendorf tubes. The extracts were dissolved in the corresponding volume of DMSO (5% 
of the total volume), and an appropriate volume of seawater was added (examples given in 
Table 3). Dissolution of the extracts in DMSO was facilitated by ultrasonication. After 
adding the seawater, the solution was well agitated by means of a vortex mixer.  
Table 3: Preparation of 2000 µg/ml stock solutions for the BSLA. 
Sample weight (mg) 
total volume 
(µl) 
volume DMSO 
(µl) 
volume water 
(µl) 
985 1.4 700 35 665 
988 1.2 600 30 570 
994 1.0 500 25 475 
998 1.5 750 38 713 
999 1.4 700 35 665 
1016 1.8 900 45 855 
1018 1.4 700 35 665 
1024 2.2 1100 55 1045 
1347 1.9 950 48 903 
1475 1.5 750 38 713 
Persea  2.1 1050 53 998 
 
3.3.3.4. Assay arrangement 
Serial dilutions were made directly in the wells of 96-well microtiter plates in 100 µl 
seawater. Control wells with 5% DMSO in artificial seawater (blank) and Persea americana 
seed extract (positive control) were included in each experiment. Nauplii were added to the 
dilutions by catching them from the petri dish with an Eppendorf pipette. Into every well 
10 nauplii (each in 10 µl artificial seawater) were transferred. 
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Figure 21: Arrangement of samples and resulting concentrations obtained by serial dilutions  
and subsequent transfer of 10 nauplii to each well. Final volume: 200 µl. 
Blank: 5% DMSO in artificial seawater  
Control: Persea americana seed extract 
 
3.3.3.5. Incubation and evaluation 
The microplates were covered and incubated at approximately 25°C in darkness. After 
24 hours, the plates were examined under a stereo microscope and the numbers of dead 
nauplii in each well were counted and noted. Nauplii were considered as dead if they did 
not show any movement during several seconds of observation.  
LC50 values and 95% confidence intervals were determined via probit analysis using the 
LC50 Program Version 2.5, a modified version of the program originally supplied by 
Stephan (1977). If the obtained data were insufficient for probit analysis, the binomial test 
was applied.  
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3.3.4. Cellular studies 
The cytotoxicity of the investigated sponges (MeOH extracts and CH2CL2/MeOH extracts) 
against several cell lines was studied using a disk diffusion assay. Differential cell killing 
among the following cell types was examined: Two leukemias (murine L1210 and human 
CCRF-CEM), three solid tumors (murine Colon 38, human Colon H116 and human lung 
H125), as well as a murine and a human normal cell line (hematopoietic progenitor cell, 
CFU-GM). Both antiproliferative response and differential activity have been the end-points 
in this in vitro assay. Solid tumor selectivity relative to normal cells and/or to their 
respective leukemia cells were positive outcomes, and human selectivity was prioritized 
over murine selectivity. The assay was designed to determine differences in the relative 
sensitivity of leukemias, solid tumors and normal cells for a given sample.  
 
Disc diffusion assay  
The test material (extract dissolved in DMSO) was placed on a filter disk which was then 
put on top of the agar plates that have been seeded with either tumor cells or normal cells. 
The zone of inhibition was examined after 7-10 days of incubation (depending upon the 
cell type) and quantified in terms of zone units. The diameter of the filter disk (6.5 mm) was 
arbitrarily taken as 200 units; samples were of further interest if the zone of inhibition 
exceeded 300 units. A difference of ≥ 250 units between any solid tumor and either 
leukemia or normal cells defined solid tumor selective samples.  
 
The cellular studies were carried out by Dr. Frederick Valeriote, Ford Cancer Center, 
Detroit, USA.  
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4. RESULTS 
The aim of the study was the isolation of the toxic compound via bioassay guided 
fractionation from an extract of a marine sponge with high cytotoxicity. The following flow 
chart shows the individual steps applied for this investigation. 
 
 
 Small-scale purification via vacuum liquid 
chromatography 
 Preliminary screening for cytotoxicity via  
the brine shrimp lethality assay 
 
 
 Brine shrimp lethality assay (definitive test) 
 Calculation of LC50 values 
 
 
 
 Large-scale purification  
 Fractionation via vacuum liquid 
chromatography 
 
 
 
 Brine shrimp lethality assay 
 Calculation of LC50 values 
 Thin layer chromatography 
 
 
 
 Analytical and semi-preparative HPLC 
 Fractionation via BioXplore© technology 
 Brine shrimp lethality assay 
 Calculation of LC50 values 
 Thin layer chromatography 
 
 
Figure 22: Sequence of individual working steps applied in the present study.   
40 crude extracts of marine sponges 
9 purified EtOH extracts active 
2 samples (998 and 999) with LC50 
values < 200 µg/ml 
5 fractions 
Selection of sample 999 for further 
investigation 
Result: BioXplore© fraction 2 was 
identified as the toxic substance 
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4.1. Selection of sponge sample for further investigation 
From a total of 40 sponge extracts (see chapter 3.1) the most suitable sample for bioassay 
guided fractionation had to be chosen. As significant cytotoxicity was the main criterion for 
further investigation, all the extracts were screened via the brine shrimp lethality assay 
(BSLA) to assess the grade of toxicity (see chapter 3.3.3). 
First, the crude extracts were subjected to a clean-up process to obtain purified ethanol 
extracts, in which the secondary metabolites of interest were allowed to concentrate. With 
these extracts, a preliminary BSLA was carried out to exclude sponge samples without 
notable toxicity against Artemia salina. The initial screening was performed under 
simplified conditions (see chapter 3.3.3.1). Only those extracts, which showed significant 
activity against Artemia salina at concentrations of ≤ 500 µg/ml, were further investigated. 
They were tested in the BSLA under the extended conditions and LC50 values were 
determined.  
For these two samples, which demonstrated the highest activity, a larger amount of crude 
extract was purified in order to obtain material for further investigation. The purified ethanol 
extracts were fractionated via vacuum liquid chromatography (VLC) (see chapter 3.3.2.1). 
The fractions were subjected to the BSLA and analyzed by means of thin layer 
chromatography (TLC) (see chapter 3.3.2.3).  
Based on the results obtained by the BSLA, the extract of the marine sponge with the code 
999 was finally selected for further investigation.  
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4.1.1. Small-scale purification of sponge samples 
Small amounts of the crude CH2Cl2/MeOH (1:1) sponge extracts, absorbed on Diaion® 
HP-20 resin, were purified using a Supelco Visiprep™ SPE Vacuum Manifold as described 
in chapter 3.3.2.1. The respective yields are given in Table 4. 
Table 4:  Purification yields of 40 sponge extracts absorbed on approx. 2 ml resin.  
Fraction 1: water; fraction 2: EtOH; fraction 3: CH2Cl2/EtOH (1:1). 
Sample 
number 
Fraction 1 
(mg) 
Fraction 2 
(mg) 
Fraction 3 
(mg) 
 
Sample 
number 
Fraction 1 
(mg) 
Fraction 2 
(mg) 
Fraction 3 
(mg) 
983 269.3 69.1 81.9 
 
1018 143.3 58.7 54.9 
984 161.5 66.7 69.9 
 
1019 150.9 108.3 124.0 
985 41.0 6.8 12.5 
 
1020 90.8 77.4 120.3 
986 100.9 54.4 89.3 
 
1021 201.4 49.9 76.9 
987 10.3 6.2 14.6 
 
1022 76.3 70.3 86.1 
988 120.1 22.4 43.4 
 
1023 36.8 20.7 34.8 
991 51.2 11.9 22.8 
 
1024 62.6 24.7 54.9 
992 74.2 12.0 21.4 
 
1344 108.3 20.7 46.2 
994 40.5 7.4 12.8 
 
1346 85.7 30.6 100.2 
995 61.5 19.8 32.6 
 
1347 211.3 42.1 94.2 
997 4.4 12.8 16.2 
 
1468 389.5 105.3 133.0 
998 60.6 30.6 21.1 
 
1469 51.1 35.2 49.3 
999 69.2 25.4 43.1 
 
1470 41.9 27.8 45.8 
1000 77.4 11.7 16.0 
 
1471 96.9 50.4 87.0 
1006 61.7 27.8 31.6 
 
1472 125.7 89.1 147.0 
1007 25.6 11.7 36.7 
 
1473 165.9 66.1 108.7 
1008 27.3 19.4 23.9 
 
1474 50.1 33.7 72.3 
1009 22.7 7.4 8.2 
 
1475 32.6 24.8 40.5 
1016 133.5 107.6 80.7 
 
1476 49.4 47.0 66.2 
1017 35.6 71.9 28.6 
 
1477 53.9 26.5 34.7 
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4.1.2. Preliminary screening for cytotoxicity 
The purified ethanol extracts (fraction 2) were subjected to the BSLA as described in 
chapter 3.3.3. Each sample was tested at concentrations of 500, 250, 125 and 62.5 µg/ml 
in duplicate. Table 5 shows the results of this initial selection step. The numbers indicate 
dead nauplii counted at each concentration of the respective sample.  
Individually occurring deaths at any concentration were disregarded, as they could be 
considered as coincidence. At this stage, the obtained data were not sufficient for 
calculation of reliable LC50 values. Thus, samples were just classified as active (at least 
three deaths in both replicates, or more than five in one test at 500 µg/ml), or not active 
(ND, no detection). Eight samples showed significant activity (sample number 987, 988, 
998, 999, 1016, 1018, 1347, and 1475), and were therefore chosen for further 
investigation. The significant higher death rate of sample number 1024 at lower 
concentrations can be explained by poor dissolution of the extract. Therefore it was also 
selected for further investigation.  
In the blank sample (5% DMSO in artificial seawater), a survival rate of 100% was 
observed. An investigated mortality of 100% in the positive control (Persea americana 
seed extract) indicate an LC50 of < 62.5 µg/ml, which is in accordance with the results 
obtained by Leite et al. (2009). 
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Table 5:  Activity of sponge samples (purified ethanol extracts) against Artemia salina. Numbers 
indicate dead nauplii counted. A: active; ND: no detection; R: retest. 
Sample 
number 
500 
µg/ml 
250 
µg/ml 
125 
µg/ml 
62.5 
µg/ml Toxicity 
 
Sample 
number 
500 
µg/ml 
250 
µg/ml 
125 
µg/ml 
62.5 
µg/ml Toxicity 
983 0 0 0 0 ND  1018 
9 5 2 2 A 0 0 0 0 
 
7 2 2 1 
984 0 0 0 0 ND  1019 
0 0 0 0 ND 0 0 1 1 
 
0 1 0 1 
985 0 0 0 0 ND  1020 
0 0 0 0 ND 0 0 0 0 
 
0 0 1 1 
986 0 1 0 0 ND  1021 
0 0 0 0 ND 0 0 0 0 
 
0 0 1 0 
987 8 0 0 0 A  1022 
0 0 0 0 ND 2 0 0 0 
 
0 0 0 0 
988 7 7 5 5 A  1023 
0 1 0 0 ND 7 6 6 6 
 
0 0 0 0 
991 2 1 0 0 ND  1024 
1 4 5 7 R 0 0 0 0 
 
0 1 2 3 
992 0 0 0 0 ND  1344 
0 0 0 0 ND 0 0 0 0 
 
0 0 0 0 
994 0 0 1 0 ND  1346 
0 0 0 0 ND 0 0 1 0 
 
0 1 0 0 
995 0 1 0 1 ND  1347 
4 2 1 1 A 0 0 1 1 
 
3 1 1 2 
997 0 0 0 0 ND  1468 
0 0 0 0 ND 0 0 0 0 
 
0 0 0 0 
998 6 5 3 2 A  1469 
0 0 0 0 ND 9 7 4 2 
 
0 0 0 1 
999 9 7 3 2 A  1470 3 1 0 0 ND 9 6 4 4   0 0 0 0 
1000 0 0 0 0 ND  1471 
0 0 0 0 ND 0 0 0 0 
 
0 0 0 0 
1006 0 0 0 0 ND  1472 
0 0 0 0 ND 0 0 0 0 
 
0 0 0 0 
1007 0 0 0 0 ND  1473 
0 0 0 0 ND 0 0 0 0 
 
1 0 0 0 
1008 0 0 0 0 ND  1474 
3 0 0 1 ND 0 0 0 0 
 
2 0 0 0 
1009 0 0 0 0 ND  1475 
8 3 0 0 A 1 0 0 0 
 
1 0 0 0 
1016 8 2 1 1 A  1476 
1 1 0 0 ND 7 3 2 2 
 
0 0 0 0 
1017 2 0 0 0 ND  1477 
0 0 0 0 ND 0 0 0 0 
 
0 0 0 0 
             Blank 0 0 0 0 ND  Persea 
10 10 10 10 A 0 0 0 0 
 
10 10 10 10 
  
48 
 
 
4.1.3. Determination of LC50 values for active samples  
Those samples, which were classified as active in the preliminary screening, were 
subjected to the BLSA over the full range of concentrations (1000, 500, 250, 125, 62.5, 
31.3, 15.6 and 7.8 µg/ml). LC50 values and 95% confidence were calculated via probit 
analysis for samples with steady results (see chapter 3.3.3.5). The results for the sponge 
samples examined in more detail can be seen from Table 6. Remarkably low LC50 values 
were calculated for sample 998 and 999 (191 µg/ml and 115 µg/ml respectively), which 
were therefore chosen for further investigation. Sample 1347 also showed significant 
activity with an LC50 value of 290 µg/ml. Sample 987 was moderately toxic (LC50 value of 
725 µg/ml). For sample 988, 1016 and 1018 no reliable LC50 values could be determined, 
because they showed inconsistent activity within the dilution series and the repetitions, 
respectively. Two samples (1024 and 1475) showed low activity within the observed 
concentration range. Hence, no LC50 values could be calculated.  
 
Table 6:  LC50 values and 95% confidence intervals calculated from results  
obtained by the BSLA for further investigated samples. 
Sample 
number LC50 (µg/ml) 95% confidence interval 
987 725 528-1178 
988 not evaluable 
998 191 131-280 
999 115 79-167 
1016 not evaluable 
1018 not evaluable 
1024 > 1000 not evaluable 
1347 290 194-459 
1475 > 1000 not evaluable 
Blank no detection 
Persea 9 (binom.) not evaluable 
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4.1.4. Purification and fractionation of two active samples 
The crude extracts of the marine sponges with the code 998 and 999 were purified as 
described in chapter 3.3.2.2. The amounts of extracts recovered in this purification process 
are shown in the following table.  
Table 7:  Purification yields of two sponge extracts absorbed on approx. 80 ml resin.  
Fraction 1: water; fraction 2: EtOH; fraction 3: CH2Cl2/EtOH (1:1). 
Sample 
number 
Fraction 1 
(mg) 
Fraction 2 
(mg) 
Fraction 3 
(mg) 
998 1831 1716 893 
999 1698 1579 682 
 
The purified ethanol extracts (fraction 2) were further fractionated by VLC (see chapter 
3.3.2.1). The respective yield of each fraction is given in Table 8. 
Table 8:  Fractionation yields of approx. 5 ml HP-20 resin charged with purified extract.  
Fraction 1: EtOH/water 2:8; fraction 2: EtOH/water 1:1; fraction 3: EtOH/water 8:2; 
fraction 4: EtOH; fraction 5: isopropanol/CH2Cl2 8:2. 
Sample 
number 
Fraction 1 
(mg) 
Fraction 2 
(mg) 
Fraction 3 
(mg) 
Fraction 4 
(mg) 
Fraction 5 
(mg) 
998_2 17.9 28.6 30.4 71.0 155 
999_2 14.9 16.7 50.4 49.1 108 
 
4.1.5. Cytotoxicity assay of VLC fractions 
The fractions of the samples 998 and 999 obtained by VLC were tested for their toxicity at 
eight different concentrations by the BSLA in triplicate. Testing conditions are described in 
chapter 3.3.3.1. LC50 values and 95% confidence intervals of the fractions which 
demonstrated toxicity can be seen from Table 9.  
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Table 9:  LC50 values and 95% confidence intervals calculated from results 
obtained by the BSLA for the samples 998 and 999. 
998_2 and 999_2: Purified ethanol extracts. 
2-1 to 2-5: VLC fractions of the corresponding extract. 
Sample 
number LC50 (µg/ml) 95% confidence interval 
998_2 203 141-297 
998_2-1 no detection 
998_2-2 no detection 
998_2-3 no detection 
998_2-4 680 492-1097 
998_2-5 71 51-99 
999_2 94 63-140 
999_2-1 no detection 
999_2-2 no detection 
999_2-3 50 31-125 
999_2-4 37 27-49 
999_2-5 203 127-348 
 
For sample 998 no toxicity was observed in the fractions 1, 2, and 3 (eluted with 
EtOH/water mixtures of different percentage). Fraction 4 (EtOH) caused dead nauplii at 
1000 and 500 µg/ml, but the major toxicity was detected in the least polar fraction 
(fraction 5, isopropanol/CH2Cl2 (8:2)) with an LC50 of 71 µg/ml. Sample 999 was 
significantly more toxic, showing LC50 values of 50 µg/ml, 37 µg/ml and 203 µg/ml in 
fraction 3 (EtOH/water (8:2)), 4 (EtOH) and 5 (isopropanol/CH2Cl2 (8:2)) respectively. 
Based on these results, sample 999 was selected for further fractionation.  
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4.1.6. Thin layer chromatography (TLC) 
The fractions of sample 999 obtained in the purification process (999_1, 999_2, 999_3) 
and the fractions obtained via VLC (1-5, sub-fractions of 999_2) were further analyzed by 
TLC as described in chapter 3.3.2.3. The plates were developed with three different mobile 
phases and detected under UV light and subsequently with two spray reagents.  
Butanol – glacial acetic acid – water (4:1:1) turned out to be the most suitable solution for 
the development of the plates, and vanillin-sulfuric acid was the more expedient 
visualization reagent. The purple spots with an Rf value of 0.56 were most probably the 
substance of interest, as toxicity for the fractions showing this spot was detected in the 
BSLA. Further, the intensity of the spots correlated with the activity of the respective 
fractions (compare marked spots and LC50 values of the corresponding fractions in 
Figure 23). 
 
 
 
 
 
 
 
  999_1 999_2  1 2  3   4 5 999_3 
LC50 (µg/ml):    94 ND  ND 50  37  203 
Figure 23: TLC of fractions obtained by VLC. 
 Stationary phase: Silica gel F254 
Mobile phase: Butanol – glacial acetic acid – water (4:1:1) 
Detection: UV254, vanillin-sulfuric acid reagent 
  
Rf: 0.56 
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4.2. Isolation of the active compound of sample 999 
As a first approach, high performance liquid chromatography (HPLC) and semi-preparative 
HPLC were applied for further fractionation of sample 999. Finally, the industrial HPLC 
system BioXplore© was used to separate the purified ethanol extract. The individual 
fractions obtained by the HPLC separations were tested in the BSLA, and TLC was used 
to monitor the process.  
 
4.2.1. Semi-preparative HPLC  
After fractionation of the purified sponge extracts via VLC and cytotoxicity testing of the 
resulting fractions against Artemia salina, the most toxic fraction 999_2-4 was further 
characterized by HPLC as described in chapter 3.3.2.4. In a first step, an analytical 
separation method was developed for further application of the semi-preparative 
fractionation. The chromatogram obtained by this method is shown in Figure 24. Six 
fractions (shown in different colors in the figure below) were collected manually in several 
runs from a total amount of approximately 20 mg.  
 
 
 
 
 
 
 
 
 F1 F2  F3  F4 F5 F6 
 
Figure 24: HPLC chromatogram of fraction 999_2-4; conditions as stated in chapter 3.3.2.4. 
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The fractions obtained by semi-preparative HPLC were evaporated to dryness and 
weighed. After purification steps via re-dissolving in methanol and filtrating with Supelco 
Supelclean™ LC-18 SPE tubes (bed wt. 500 mg, volume 6 ml) and Acrodisc® LC PVDF 
syringe filters (0.45 µm, 25 mm), the recovery was approximately 200%. As it was not 
significantly affecting the final results, no further separation of the contaminant was 
necessary. 
 
4.2.2. Cytotoxicity assay of HPLC fractions 
The activity of the HPLC fractions against Artemia salina was tested at eight different 
concentrations in triplicate, and LC50 values were calculated for the toxic fractions. The 
obtained results are shown in Table 10. Fraction 5 and 6 showed activity in the BSLA, with 
similar LC50 values compared to the unfractionated extract. This can be explained by 
dilution with the non-filterable contaminant (see above).  
Table 10:  LC50 values and 95% confidence intervals calculated from results 
obtained by the BSLA for HPLC fractions. 
Sample number LC50 (µg/ml) 95% confidence interval 
999_2-4 114 63-250 
999-HPLC_1 no detection 
999-HPLC_2 no detection 
998-HPLC_3 no detection 
999-HPLC_4 no detection 
999-HPLC_5 136 102-182 
999-HPLC_6 111  81-151 
 
The chromatogram obtained by UV detection (see Figure 24) did not show a specific peak 
which could be assigned to the toxic component. Therefore, in a next step the preparative 
HPLC system BioXplore© was applied, which was equipped with an evaporative light 
scattering detector (ELSD) in addition to a variable wavelength detector.   
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4.2.3. Fractionation via BioXplore© technology 
The advantage of the BioXplore© technology was used in order to separate more fractions 
from more volume within less time. Approximately 50 mg of purified sponge extract 999_2 
were fractionated by means of the BioXplore© HPLC unit (see chapter 3.3.2.5 for system 
information). The extract was dissolved in 20 ml EtOH, and the whole solution was 
injected. Elution was achieved with a step gradient of EtOH and water as described in 
chapter 3.3.2.5. Six fractions were collected based on the signal provided by the ELSD 
(green peaks in the figure below), evaporated to dryness and weighed. 
 
 
 
 
 
 
 
 
 
 
 
  F 1 F 2  F 3 F 4 F 5  F 6 
min    1-10  16-19    23-24  30-32   35-38 40-41 
weight (mg) 19.7   17.2  1.8 6.1 7.0  1.8 
Figure 25:  HPLC chromatogram of the purified sponge extract 999_2. BioXplore© fractionation 
technology, water/EtOH step gradient; see chapter 3.3.2.5 for further conditions. Green 
peaks: ELSD signal; blue: UV-detection. ELSD peak-based collection of six fractions at 
the times indicated. 
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ELS detection indicated clearly the elution of the compounds, and signal strength 
correlated well with the yielded amounts (compare size of the green ELSD peaks and 
corresponding weights given below). 
 
4.2.4. Cytotoxicity assay of BioXplore© fractions 
The fractions obtained through separation by BioXplore© technology were tested in the 
BSLA at eight different concentrations in triplicate, and LC50 values were calculated. 
Table 11 shows the results of this assay. 
Table 11:  LC50 values and 95% confidence intervals calculated from results obtained 
by the BSLA for BioXplore© fractions of the purified sponge extract 999_2. 
Sample number LC50 (µg/ml) 95% confidence interval 
999_2 162 110-241 
999-BX_1 no detection 
999-BX_2 73  31-125 
998-BX_3 no detection 
999-BX_4 no detection 
999-BX_5 no detection 
999-BX_6 no detection 
 
Fraction 2, which was collected from minute 16-19, yielded an LC50 of 73 µg/ml and was 
the only toxic fraction. For further analysis of this fraction and for comparison of the VLC-, 
HPLC- and BioXplore©-fractions among each other, TLC was applied. 
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4.2.5. Comparison of fractions via TLC 
The fractions obtained by VLC, semi-preparative HPLC and BioXplore© fractionation were 
further identified by TLC. As mobile phase, butanol – glacial acetic acid – water (4:1:1), 
which already proved to be appropriate for the VLC fractions (see chapter 4.1.6, 
Figure 23), was used. Visualization was carried out via vanillin-sulfuric acid reagent. In the 
obtained chromatogram (Figure 26), a spot with an Rf value of 0.53 could be seen at each 
fraction for which toxicity in the BSLA has been detected.  
 
 VLC fractions   HPLC fractions  BioXplore© fractions 
 
 
 
 
 
 
      999_2 1 2 3  4  5  999_2-4 1   2  3    4   5  6 999_2  1  2  4  5 
LC50:  94   ND   ND   50    37   203 114   ND ND   ND    ND   136   111 162 ND 73   ND   ND  
Figure 26: TLC of the fractions obtained by VLC, semi-preparative HPLC and BioXplore© 
fractionation.  
Stationary phase: Silica gel F254 
Mobile phase: Butanol – glacial acetic acid – water (4:1:1) 
Detection: UV254, vanillin-sulfuric acid reagent 
LC50 values (µg/ml) as calculated in chapter 4.1.5 (VLC fractions), chapter 4.2.2 (HPLC 
fractions) and chapter 4.2.4 (BioXplore© fractions). 
  
Rf: 0.53 
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4.2.6. Cellular studies 
The results of the cellular studies (carried out by Dr. Frederick Valeriote, Ford Cancer 
Center, Detroit, USA) for the extracts of the marine sponge with the code 999 can be seen 
from Table 12. Murine L1210 and human CCRF-CEM are leukemia cells, murine colon 38, 
human colon H116 and human lung H125 are solid tumor cells, and murine CFU-GM is a 
normal cell. An extract is of sufficient activity to be of further interest, if the zone of 
inhibition exceeded 300 units (see chapter 3.3.4). The methanol extract of sample 999 was 
of significant toxicity to all cell types which were tested.  
 
Table 12: Results obtained by the cellular studies for sample 999.  
Cell types MeOH extract 
(units) 
CH2CL2/MeOH extract 
(units) 
Murine L1210 650 250 
Human CCRF-CEM 550  
Murine colon 38 650 350 
Human colon H116 500 100 
Human lung H125 500 200 
Murine CFU-GM 550 200 
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5. DISCUSSION 
Marine sponges are well known to produce structurally diverse cytotoxic compounds as a 
defense strategy. These bioactive secondary metabolites are an important source of novel 
pharmacologically active agents. They provide lead compounds for the treatment of a 
variety of human diseases, most of them showing antitumor potential (Hentschel & 
Bringmann 2010). In the present study, 40 extracts of marine sponges were tested for their 
cytotoxicity, and the sponge extract with the highest toxicity was selected for further 
investigation. The active component of this extract was isolated via bioassay guided 
fractionation. The bioassay applied to investigate the activity of marine sponges was the 
brine shrimp lethality assay (BSLA). 
The sponges studied in this work were collected in 2002 and 2003 in the Caribbean Sea of 
Costa Rica and extracted via ultrasonic-assisted solvent extraction. Ultrasonic-assisted 
solvent extraction is a modified maceration method, where the extraction of metabolites is 
facilitated and yields are improved. Ultrasonication induces a mechanical stress on the 
cells through formation of cavitations in the sample, resulting in cellular breakdown and 
thus increased solubilization of intracellular metabolites (Seidel 2006). The solvents mainly 
used for sponge extraction are MeOH (Bao et al. 2007; Ridley & Faulkner 2003) and a 1:1 
mixture of MeOH and CH2Cl2 (Coello et al. 2009; Pettit et al. 2004), respectively. Further, 
EtOH (Oku et al. 2003) and mixtures of EtOH/CHCl3 have been used (Ponomarenko et al. 
2007). In this study, the solvent mixture CH2Cl2/MeOH (1:1) was chosen to obtain a broad 
spectrum of secondary metabolites in terms of polarity.  
For purification and fractionation of the sponge extracts, vacuum liquid chromatography 
(VLC) was applied. The development of VLC proceeded in the 1970s, arousing from the 
need to have a simple, inexpensive chromatographic system capable of producing good 
resolution in a short time. Coll et al. first investigated the potential of this technique in 1977 
by applying it to the isolation of a cembrenoid diterpene from an Australian soft coral. 
Detailed descriptions of the method were published some years later (Targett et al. 1979; 
Coll & Bowden 1986). Manipulations, e.g. solvent changes are easy, because the head of 
the column is at atmospheric pressure (Hostettmann et al. 1998). The application of VLC 
increased in the last decade, mainly for the fractionation of natural products prior to other 
chromatographic systems such as medium-pressure liquid chromatography (MPLC) and 
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high performance liquid chromatography (HPLC). In some cases it is used as the only 
separation step (Sticher 2008).  
Purification of the crude sponge extracts was carried out via elution with water, EtOH and 
CH2Cl2/EtOH (1:1) in order to obtain purified ethanol extracts, in which the secondary 
metabolites of interest were allowed to concentrate. Through this extraction steps, highly 
polar substances, e.g. salts and sugars, and non-polar substances, e.g. fats were 
separated. Small-scale purification of 40 sponge extracts was performed with a Supelco 
Visiprep™ SPE Vacuum Manifold, 12-Port Model, which allowed the purification of up to 
12 sponge extracts simultaneously. It therefore helped to obtain purified material for the 
initial cytotoxicity screening via the BSLA within a short time. 
The BSLA is a useful tool for the preliminary toxicity assessment (Carballo et al. 2002; 
Lopes et al. 2010). It was proposed by Michael et al. (1956), later developed by 
Vanhaecke et al. (1981) and Sleet and Brendel (1983). The BSLA is based on the ability of 
test materials to kill laboratory-cultured Artemia salina (brine shrimp) nauplii. It allows to 
determine LC50 values of active compounds and extracts and to detect a broad spectrum 
of pharmacologic activities. The method is rapid, reliable and inexpensive, and is therefore 
a very suitable bioassay for screening and fractionation monitoring of active materials 
(Meyer et al. 1982).  
Brine shrimp are typically found in hypersaline lakes and ponds, habitats of low species 
diversity and simple trophic structures (Lenz & Browne 1991). They possess uncommon 
adaptability to extreme environmental conditions such as large ranges of salinity  
(5-250 g/L) and temperature (6 to 36°C), as well as varied nutrient sources. Reproduction 
can be performed either sexually or parthenogenetically, with nauplii or cysts production. 
Nauplii are free-swimming larvae spawned under optimal conditions. Resistant embryos 
(cysts) are produced when environmental conditions get unfavorable, such as increase in 
salinity with eventual desiccation and decreasing temperatures (Nunes et al. 2006). Dried 
cysts of the brine shrimp can be stored for years without losing their viability, and, upon 
immersion in seawater, the nauplii will hatch within 24 hours (Vanhaecke et al. 1981) and 
can be used for the BLSA.  
Toxicity tests with the crustacean Artemia salina have been applied in many different 
fields, e.g. for the detection of fungal toxins (González et al. 2007), cyanobacteria toxins 
(Lopes et al. 2010), plant extract toxicity (Krishnaraju et al. 2006; Kusuma et al. 2011), 
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detection of pesticides (Bustos-Obregon & Vargas 2010) and warfare agents (Lumor et al. 
2011), cytotoxicity testing of dental materials (Milhem et al. 2008) and marine natural 
products (Carballo et al. 2002; Mansoor et al. 2007), and in ecotoxicity testing (Nunes et 
al. 2006). In contrast to the mainly used BSLA, an alternative assay with Artemia salina is 
based on the inhibition of hatching of the cyst (hatchability assay) (Carballo et al. 2002). In 
the lethality assay - which was performed in the present work - Artemia salina larvae were 
exposed to test samples in saline solution and lethality was evaluated after 24 hours. The 
inexpensiveness and commercial availability of Artemia salina cysts, as well as the low 
cost and ease of performing the test, make the brine shrimp lethality assay a very useful 
bench-top method (Krishnaraju et al. 2006).  
In the present work, the BSLA was performed in 96-well microtiter plates as developed by 
Solis et al. (1993). Other tests, carried out in petri dishes (Vanhaecke et al. 1981), vials 
(Meyer et al. 1982) or multiwell culture plates (Carballo et al. 2002) use sample solutions 
of 5 to 10 ml. Disadvantages thereof are, that relatively large amounts of test material are 
required and preparation of the dilutions is time-consuming. In contrast to these methods, 
the microplate assay is performed with small sample volumes (e.g. 200 µl). The varying 
concentrations of test solutions are directly prepared in the microplate wells via serial 
dilutions. The employment of micro-technique therefore allows an economic screening of 
large numbers of samples and dilutions (Solis et al. 1993).  
In the BSLA, the cytotoxicity was evaluated on an extract of Persea americana (avocado) 
seeds, which was used as positive control. Activity of Persea americana seed extracts in 
the BSLA was investigated by Leite et al. (2009). In the preliminary screening, the 
detected activity for 2 samples (2 replicates each) differed widely (8 and 2 dead nauplii in 
sample 987, 8 and 1 in sample 1475 at a concentration of 500 µg/ml). The solubilizer used 
was 5% DSMO. The high variability of the results may be due to poor dissolution and 
inhomogeneity of the test solutions respectively. Since DSMO was not the appropriate 
solvent for all sponge extracts, other solvents, e.g. MeOH (as used by Meyer et al. 1982) 
could be tested in further studies. 
From a total of 40 sponge extracts, two of the samples (998 and 999) demonstrated high 
toxicity (LC50 values < 200 µg/ml) with high reproducibility. These two samples were further 
fractionated via VLC, the obtained fractions were subjected to the BSLA and LC50 values 
were calculated. The samples 998 and 999 demonstrated activities against Artemia salina 
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in two and in three fractions, respectively. Sample 998 showed low toxicity in fraction 4 
(EtOH) with an LC50 value of 680 µg/ml and high toxicity in fraction 5 (isopropanol/CH2Cl2 
(8:2)) with an LC50 value of 71 µg/ml. Fraction 3 (EtOH/water (8:2)), 4 (EtOH) and 5 
(isopropanol/CH2Cl2 (8:2)) of sample 999 showed high toxicity with LC50 values of 
50 µg/ml, 37 µg/ml and 203 µg/ml, respectively. Based on these results, sample 999 was 
chosen for further investigation. 
The fractions of sample 999 obtained by VLC were further analyzed via thin layer 
chromatography (TLC). TLC is a simple, rapid and inexpensive separation method which 
can be used both as an analytical and a preparative technique. With regard to natural 
product isolation, analytical TLC is widely applied for the detection of compounds through 
several separation steps. It further helps to select an appropriate system for column 
chromatography, and assists in assessing the degree of purity of isolated compounds 
(Houssen & Jaspars 2006). In the chromatogram obtained from the VLC fractions of 
sample 999 (see chapter 4.1.6, Figure 23), a spot with an Rf value of 0.56 could be seen in 
the fractions 3 and 4, which showed high toxicity in the BSLA. The spot was also visible - 
to a lesser extent - in fraction 5, which showed lower toxicity. As the intensity of the spots 
directly correlates with the activity in the BSLA, this spot is most likely the toxic 
component.  
For further characterization and separation of sample 999, the most toxic fraction 
(fraction 4) obtained by VLC was first subjected to analytical HPLC separation, further 
semi-preparative HPLC was applied. HPLC is a powerful separation technique which has 
become a mainstay for natural product isolation and purification, regardless to their 
source. Due to various modes available, e.g. normal-phase, reversed-phase, size 
exclusion, and ion exchange HPLC, it is applicable to purify most classes of natural 
products. Reversed-phase HPLC (RP-HPLC) is the most common technique used for 
analysis and purification of compounds from a complex matrix, especially when the identity 
of the compounds of interest is unknown (Latif 2006). The fractions obtained by semi-
preparative HPLC were subjected to the BSLA and LC50 values were calculated. 
Compared to the results of the VLC fractions obtained by the cytotoxicity assay, the LC50 
values were consistently higher. The decrease of toxicity in the VLC fraction (999_2-4, 
LC50 37 µg/ml vs. 114 µg/ml) may be due to instability of the active component. The toxic 
HPLC fractions showed similar activity compared to the unfractionated extract, which can 
be explained by dilution with the non-filterable contaminant (see chapter 4.2.2). 
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For further separation of sample 999, the advantage of the BioXplore© Varian equipment 
to separate more fractions from more volume within less time was used. The BioXplore© is 
an industrial HPLC system which can be applied for removing concomitant compounds 
such as salts, carbohydrates and major fatty acids of crude extracts, as well as for 
fractionating different types of samples. Plant material, marine organisms, culture broths 
and other extracts can be separated. Up to 48 fractions are automatically collected within 
one run, optionally by time or by volume. Columns with a capacity of 500 ml or 1000 ml 
can be applied, providing a loading capacity of several grams. The unit is equipped with 
two detectors in parallel, a variable wavelength detector and an evaporative light scattering 
detector (ELSD). In contrast to UV detection, which depends on the capacity of 
compounds to absorb light, the extinction coefficients of the analytes have no effect on the 
response of ELSD. The signal resulting from ELSD directly correlates with the 
concentration of compounds present in the sample (Houssen & Jaspars 2006). From the 
chromatogram obtained by separation with the BioXplore© instrument can be seen, that 
the ELSD signal clearly indicates the elution of the compounds, whereas almost no UV 
signal could be observed. As the compounds present in the extract are not UV absorptive, 
the chromatogram obtained by the Waters HPLC instrument with solely UV detection did 
not show the elution of the toxic substance. 
The fractions of the BioXplore© separation were collected based on the ELSD signal and 
tested via the BSLA. For fraction 2, the peak collected from minute 16-19, an LC50 value of 
73 µg/ml was calculated. Decrease of toxicity was clearly observable for the unfractionated 
sponge extract 999_2, which showed an LC50 value of 162 µg/ml vs. 94 µg/ml in the BSLA 
performed with the VLC fractions (see chapter 4.1.5, Table 9). A similar decrease of 
toxicity could already be seen in the BSLA for the HPLC fractions and was probably due to 
instability of the active component.   
Finally, the fractions obtained by VLC, HPLC and BioXplore© technology were subjected 
to TLC. The obtained chromatogram showed spots with an Rf value of 0.53. This 
characteristic spot could be seen in each fraction, for which toxicity in the BSLA has been 
observed. Hence, this substance (fraction 2 of the BioXplore© fractionation) could be 
identified as the toxic component.   
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In former cellular studies carried out by Dr. Frederick Valeriote (Ford Cancer Center, 
Detroit, USA), high toxicity for the methanol extract of sponge sample 999 against several 
human and murine cell lines (see chapter 4.2.6, Table 12) has been investigated.  
   
The results obtained in this work proved high toxicity of the investigated marine sponge 
against Artemia salina, and demonstrated the great potential of bioassay guided fraction 
for the isolation of pharmacologically active compounds from the complex matrixes of 
natural products. The present study further confirms the suitability and efficiency of the 
BSLA carried out as a microplate assay for the assessment of cytotoxicity. Additionally, the 
great capacity of the BioXplore© technology for the fractionation of extracts has been 
shown.  
In further studies, the validation of the purity and the structural elucidation of the cytotoxic 
compound via nuclear magnetic resonance (NMR) spectroscopy are being accomplished 
by the research team of the Bioprospecting Strategic Action Unit of INBio. 
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6. SUMMARY 
Marine sponges (Porifera) comprise a rich source of novel pharmacologically active 
compounds. A major part of them shows cytotoxic properties, hence, these substances are 
potential antitumor agents. 
 
The aim of this study was the isolation of the toxic component from a selected sponge 
extract after preliminary screening a potential toxic activity of a set of marine sponges. 
Therefore, purified ethanol extracts of 40 Caribbean marine sponges, which were obtained 
by ultrasonic-assisted solvent extraction with CH2Cl2/MeOH (1:1) and purified via vacuum 
liquid chromatography (VLC), were tested applying the brine shrimp lethality assay 
(BSLA). The BSLA, which was carried out as a microplate assay, allowed to determine the 
toxicity of the marine sponge extracts against Artemia salina (brine shrimp) larvae and 
also, to calculate LC50 values via probit analysis. The extract with the highest toxic activity, 
which was obtained from a marine sponge of the order Haplosclerida, showed an 
LC50 value of 94 µg/ml and was further investigated via bioassay guided fractionation. 
 
The isolation of the toxic component from the selected sponge extract was performed by 
various chromatographic methods. VLC was applied for initial fractionation, and further 
separation was carried out via high-performance liquid chromatography (HPLC). The 
fractionation of the individual components was finally achieved by means of the 
preparative HPLC system BioXplore© (Varian). The individual fractions obtained by VLC 
and HPLC were tested for their toxicity via the BSLA. Further, thin layer chromatography 
(TLC) was used to monitor the fractionation processes. Based on the results obtained by 
the BSLA, one specific BioXplore©-fraction was identified as the toxic component of the 
investigated sponge extract. 
 
This study was considered as a highly important basic work for further structural 
elucidation of the compound of interest, which is being accomplished at the Bioprospecting 
Strategic Action Unit of INBio.  
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7. ZUSAMMENFASSUNG 
Meeresschwämme (Porifera) stellen eine reiche Quelle neuartiger pharmakologisch 
aktiver Verbindungen dar. Ein großer Teil davon zeigt zytotoxische Eigenschaften, 
weshalb diese Substanzen als potenzielle Antitumor-Wirkstoffe gelten. 
Ziel dieser Arbeit war, die toxische Komponente eines Meeresschwamm-Extrakts zu 
isolieren, welcher zuvor aus einem Set von Extrakten mittels Toxizitäts-Screening 
ausgewählt wurde. Dazu wurden aufgereinigte Ethanol-Extrakte von 40 karibischen 
Meeresschwämmen, die durch Extraktion mit dem Lösungsmittelgemisch CH2Cl2/MeOH 
(1:1) gewonnen und mittels Vakuum-Flüssigchromatographie (VLC) aufgereinigt wurden, 
anhand eines Bioassays (brine shrimp lethality assay, BSLA) auf Zytotoxizität getestet. Mit 
dem BSLA, welcher in Form eines Mikroplatten-Assays durchgeführt wurde, konnte die 
Toxizität der Extrakte gegenüber Artemia salina (Salinenkrebs)-Larven bestimmt und 
LC50-Werte anhand der Probit-Analyse berechnet werden. Der Extrakt mit der stärksten 
toxischen Aktivität, gewonnen von einem Meeresschwamm der Ordnung Haplosclerida, 
zeigte einen LC50-Wert von 94 µg/ml und wurde mittels Bioassay-geleiteter Fraktionierung 
näher untersucht.  
Die Isolierung der toxischen Komponente des ausgewählten Meeresschwamm-Extrakts 
erfolgte mit Hilfe verschiedener chromatographischer Methoden. Begonnen wurde mit 
einer Fraktionierung mittels VLC, und die weitere Auftrennung erfolgte anhand von 
Hochleistungs-Flüssigchromatographie (HPLC). Die Separation der einzelnen 
Komponenten wurde schließlich mit Hilfe des präparativen HPLC-Systems BioXplore© 
(Varian) erreicht. Die mit Hilfe von VLC und HPLC erhaltenen Fraktionen wurden im BSLA 
auf ihre Toxizität getestet und der Fraktionierungs-Prozess mittels Dünnschicht-
chromatographie (TLC) überprüft. Basierend auf den Ergebnissen des BSLA konnte eine 
spezifische BioXplore©-Fraktion als die toxische Komponente des untersuchten 
Meeresschwamm-Extrakts identifiziert werden. 
Diese Arbeit stellte die Grundlage für die Strukturaufklärung der zytotoxischen Verbindung 
dar, welche an der Bioprospecting Strategic Action Unit von INBio in einer weiteren Studie 
durchgeführt wird. 
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Figure 1: Diversity of marine sponges in size, shape and color. The common bath 
sponge Spongia officinalis (A), the giant barrel sponge Xestospongia 
muta (B), the branching sponge Axinella dissimilis (C and D). (Source: 
Encyclopedia of Life; www.eol.org) 
5 
Figure 2: Schematic diagram of a sponge. Arrows indicate the direction of water 
flow through the sponge. Image used with kind permission from Taylor et 
al. (2007). 
6 
Figure 3: Porifera body structures. Yellow: pinacocytes; red: choanocytes; grey: 
mesohyl; blue arrow: water flow. Source: Invertebrate Zoology (Ruppert 
et al. 2004). 
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Figure 4: Chemical structure of cryptophycins. 10 
Figure 5: Naturally occurring nucleosides spongouridine and spongothymidine, and 
synthetic compounds cytarabine (cytostatic), vidarabine and aciclovir 
(virustatics).  
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Figure 6: Ziconotide, a linear 25 amino acid peptide with three disulfide bridges. 16 
Figure 7: A practicable semi-synthesis of ecteinascidin-743 (right) from cyano-
safracin B (left) was achieved by PharmaMar researchers. 
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Figure 8: Halichondrin B, a cytotoxic compound isolated from marine sponges, and 
the truncated synthetic analogue eribulin mesylate (E7389). 
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Figure 9: Plitidepsin (Aplidin®), a depsipeptide isolated from the tunicate Aplidium 
albicans. 
20 
Figure 10: Discodermolide, isolated from the marine sponge Discodermia dissoluta. 
(Photo courtesy of Florida Atlantic University, Harbor Branch 
Oceanographic Institute.) 
21 
Figure 11: Chemical structures of the naturally occurring compound hemiasterlin 
(isolated from the sponge Hemiasterella minor), and the synthetic 
analogues E7974 and HTI-286. 
22 
Figure 12: The antimitotic peptide dolastatin 10, isolated in the 1970’s from the sea 
hare Dolabella auricularia, was the first member of the dolastatin family 
which entered clinical trials.  
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Figure 13: Chemical structures of cyclodepsipeptides produced by marine 
organisms. 
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Figure 14: Voucher specimen (A and B) and characteristic spicules (C and D) of the 
further investigated marine sponge. 
26 
Figure 15: Supelco Visiprep™ SPE Vacuum Manifold, used for small-scale 
purification of the crude sponge extracts. 
31 
Figure 16: The charging station (A), equipped with a high-pressure column (B), was 
used for purification of crude extracts.  
33 
Figure 17: Industrial HPLC unit BioXplore 300, custom made by Varian.  36 
Figure 18: Step gradient applied for fractionation via BioXplore© technology.  37 
Figure 19: Magnified view of Artemia salina.  
(Source: www.flickriver.com/photos/xavipat/4451152486) 
38 
Figure 20: Hatching of Artemia salina nauplii at 28-30°C under aeration and 
illumination for 24 h.  
39 
Figure 21: Arrangement of samples and resulting concentrations obtained by serial 
dilutions and subsequent transfer of 10 nauplii to each well. Final volume: 
200 µl. 
41 
Figure 22: Sequence of individual working steps applied in the present study. 43 
Figure 23: TLC of fractions obtained by VLC. Stationary phase: Silica gel F254. 
Mobile phase: Butanol – glacial acetic acid – water (4:1:1). Detection: 
UV254, vanillin-sulfuric acid reagent. 
51 
Figure 24: HPLC chromatogram of fraction 999_2-4; conditions as stated in chapter 
3.3.2.4. 
52 
Figure 25: HPLC chromatogram of the purified sponge extract 999_2. BioXplore© 
fractionation technology, water/EtOH step gradient; see chapter 3.3.2.5 
for further conditions. Green peaks: ELSD signal; blue: UV-detection. 
ELSD peak-based collection of six fractions at the times indicated. 
54 
Figure 26: TLC of the fractions obtained by VLC, semi-preparative HPLC and 
BioXplore© fractionation.  
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